Data from Unraveling the Cellular Mechanism of Assembling Cholesterols for Selective Cancer Cell Death

Abstract

<div>Abstract<p>Acquired drug resistance remains a challenge in chemotherapy. Here we show enzymatic, <i>in situ</i> assembling of cholesterol derivatives to act as polypharmaceuticals for selectively inducing death of cancer cells via multiple pathways and without inducing acquired drug resistance. A conjugate of tyrosine and cholesterol (<b>TC</b>), formed by enzyme-catalyzed dephosphorylation of phosphorylate TC, self-assembles selectively on or in cancer cells. Acting as polypharmaceuticals, the assemblies of TC augment lipid rafts, aggregate extrinsic cell death receptors (e.g., DR5, CD95, or TRAILR), modulate the expression of oncoproteins (e.g., Src and Akt), disrupt the dynamics of cytoskeletons (e.g., actin filaments or microtubules), induce endoplasmic reticulum stress, and increase the production of reactive oxygen species, thus resulting in cell death and preventing acquired drug resistance. Moreover, the assemblies inhibit the growth of platinum-resistant ovarian cancer tumor in a murine model. This work illustrates the use of instructed assembly (iA) in cellular environment to form polypharmaceuticals <i>in situ</i> that not only interact with multiple proteins, but also modulate membrane dynamics for developing novel anticancer therapeutics.</p>Implications:<p>As a multifaceted strategy for controlling cancer cell death, iA minimized acquired resistance of cancer cells, which is a new strategy to amplify the genetic difference between cancer and normal cells and provides a promise for overcoming drug resistance in cancer therapy.</p><p><b>Visual Overview:</b> <a href="http://mcr.aacrjournals.org/content/molcanres/17/4/907/F1.large.jpg" target="_blank">http://mcr.aacrjournals.org/content/molcanres/17/4/907/F1.large.jpg</a>.</p></div>